We use cookies to ensure that we give you the best experience on our website Learn more

Home

Saved research

Submission

CLINICALLY AVAILABLE BIOMARKERS AS PREDICTORS OF ATRIAL FIBRILLATION IN PATIENTS WITH CRYPTOGENIC STROKE THE NORDIC ATRIAL FIBRILLATION AND STROKE STUDY (NOR-FIB)

Submitted

and 17 other(s)

84 Views
0 Downloads
0 Saves

Presented at

ESOC-2019

-

Presentation

thumbnail

Abstract

Introduction Widely utilized cardiovascular and novel biomarkers have been suggested as the indicators of atrial fibrillation (AF) in patients with cryptogenic stroke. None of these are established in clinical praxis for selecting patients for prolonged cardiac rhythm monitoring. In the ongoing Nordic Atrial Fibrillation and Stroke study (NOR-FIB) we evaluate the incidence of AF in patients with cryptogenic stroke using insertable cardiac monitors, and measure the biomarker levels. The purpose of the interim analysis from our center was to evaluate whether clinically available biomarkers show association with AF detected before 6-month follow-up. Method Blood samples from 53 patients were collected in the period from January 2017 to January 2019 in Østfold Hospital Trust with 40 patients reaching 6-month follow-up. TnI, BNP, fibrinogen, and D-dimer levels were measured. Mann-Whitney U test was performed to compare biomarker levels between patients with and without detected AF. Area under the receiver operating characteristic curve (AUC) was calculated for all of the tested biomarkers. Individual odds ratios (OR) were further computed. Results By 6 months, the AF detection rate was 27,5%. Mean (±SD) times to inclusion after the index event and to AF detection after inclusion were 9.3±3.4 days and 55.7±66.4 days respectively. Significant differences between the groups were found in TnI levels. The highest AUC was observed for TnI (0.742) as well as significant association with AF, OR 8.0 95% CI (1.65, 38.79). No significant association was found for the other biomarkers. Conclusion New interim analyses with updated results including other biomarkers will be presented.

Datasets

No datasets are available for this submission.

License

No license information is available for this submission.

Morressier

Company

Legal

Follow us

© Copyright 2020 Morressier GmbH. All rights reserved.

Morressier

© Copyright 2020 Morressier GmbH.
All rights reserved.